(-)-Blebbistatin in Transparent Cardiac MEAs
2026-08-29
Discover how (-)-Blebbistatin can serve as a reversible non-muscle myosin II inhibitor in multimodal cardiac experiments. This article connects actomyosin perturbation with transparent, stretchable microelectrode arrays to improve interpretation of cardiac electrophysiology, metabolism, and mechanics.
Anagliptin Vasorelaxation: Kv and SERCA Mechanisms
2026-08-28
A 2025 Acta Diabetologica study shows that anagliptin relaxes phenylephrine-contracted rabbit aortic rings through pharmacologically defined involvement of voltage-dependent potassium channels and the SERCA pump. The endothelium-independent response was not reduced by cyclic nucleotide pathway inhibitors or blockers of several other potassium channel classes, refining how vascular actions of this DPP-4 inhibitor can be investigated.
Early Life Adversity, Oxytocin, and Defensive Behavior
2026-08-28
A 2026 Communications Biology study links early life adversity in mice to impaired looming-evoked innate defensive behavior through oxytocin-related signaling in the superior colliculus. The combination of developmental stress modeling, receptor manipulation, circuit analysis, and intranasal oxytocin rescue provides a mechanistic framework for studying how early experience alters threat processing.
Epalrestat and the Polyol Pathway in Cancer Assays
2026-08-27
Epalrestat is an aldose reductase inhibitor that can help researchers test how glucose-derived fructose and redox changes influence cancer-cell metabolism. This article translates recent fructose-metabolism findings into practical assay design while defining the compound’s evidence boundaries.
AG-221 and the Metabolic Logic of IDH2-Mutant AML
2026-08-27
AG-221 (Enasidenib) offers translational researchers a mechanistically grounded way to connect mutant IDH2 inhibition, 2-hydroxyglutarate reduction, and leukemia cell differentiation. This article extends beyond conventional product-page claims by incorporating CD44-mediated metabolic rewiring, resistance biology, assay design, and biomarker strategy for acute myeloid leukemia research.
Cyclophosphamide: Mechanism to Translation
2026-08-26
A translational framework for using Cyclophosphamide as both an alkylating chemotherapeutic agent and an immune-modulating research tool, linking hepatic activation, DNA damage, apoptosis, model selection, formulation discipline, and infection-aware study design.
Masitinib (AB1010): KIT/PDGFR Workflow
2026-08-26
Masitinib (AB1010), SKU A2942, is a DMSO-soluble phenylaminothiazole-type inhibitor for research focused on KIT, PDGFRα, PDGFRβ, selected KIT mutants, and mast-cell responses. It is best suited to controlled in vitro or preclinical workflows and should not be used as a broad-spectrum kinase tool or added directly to aqueous or ethanol-based systems.
Amikacin disulfate: Applied Assay Workflows
2026-08-25
Amikacin disulfate supports complementary workflows spanning antibiotic mechanism of action, protein–drug binding, and bacterial protein synthesis suppression. This guide translates a lysozyme-binding study into practical spectroscopy, activity, docking, and resistance-research assay designs.
SD 169: Rethinking p38 MAPK Translation
2026-08-25
SD 169 (indole-5-carboxamide) offers translational researchers a selective ATP-competitive way to interrogate p38α and p38β biology across immune, metabolic, and neural models. This article connects established pathway pharmacology with emerging evidence that inhibitor-bound p38α conformations can influence phosphatase-mediated dephosphorylation, while defining the experiments needed to distinguish target engagement from downstream phenotype.
Leptin Fragment Strategy for Translational Research
2026-08-24
A translational framework for using Leptin (116-130), amide, mouse as a sequence-defined probe of energy homeostasis, leptin-responsive biology, and inflammation—while avoiding unsupported leaps from metabolic models to cardiovascular disease.
Anagliptin (SK-0403) in Vascular Research
2026-08-23
Anagliptin (SK-0403) combines a well-defined DPP-4 inhibition mechanism with a practical model for investigating vascular Kv channel modulation and SERCA pump regulation. This guide translates rabbit aortic-ring findings into reproducible workflows, assay controls, and troubleshooting decisions for diabetes and cardiovascular research.
Ertugliflozin: From SGLT2 Biology to Translation
2026-08-22
A translational perspective on PF-04971729, connecting selective renal glucose transport inhibition with assay strategy, cardiovascular evidence, and carefully bounded opportunities in inflammatory disease models.
IR-820: Designing Better In Vivo Imaging Assays
2026-08-21
IR-820, also known as New Indocyanine Green, can support more informative vascular and tumor studies when fluorescence is interpreted alongside tissue biology and assay controls. This guide presents a decision-focused framework for near-infrared fluorescence imaging, formulation selection, and careful translation of photothermal nanomedicine evidence.
Selective Autophagy Tunes IRF3 Stability and IFN
2026-08-21
Wu et al. identify a virus-load-dependent pathway in which CALCOCO2/NDP52-mediated selective autophagy degrades IRF3, while PSMD14 preserves IRF3 by removing K27-linked ubiquitin chains at lysine 313. The study explains how opposing turnover mechanisms calibrate type I interferon signaling and limit excessive immune activation.
Bovine Insulin for hDPSC Assay Workflows
2026-08-20
Build more interpretable dental pulp stem-cell experiments by pairing bovine insulin with proliferation, metabolism, differentiation, and senescence readouts. This workflow uses the Biodentine aging study as a design anchor while keeping insulin-specific effects experimentally separable.
460 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page